Pfizer Inc. (NYSE: PFE) today announced that it has received FDA approval for the development of a novel generic version of its Celebrex arthritis pain reliever, Vioxx (rofecoxib). The new version of Celebrex (celecoxib) is scheduled to be submitted for marketing approval in late December. Pfizer’s global Celebrex sales increased by $11.1 billion in 2014 and $15.5 billion in 2015, to $3.6 billion, or $0.4 billion, in the United States, compared with $2.8 billion, or $0.1 billion, in the previous 12 months.
“We are pleased to receive FDA approval for Vioxx for the first time, and we are confident that this new product will be a game-changer in pain management,” said John R. Kennedy, Jr., Chairman and Chief Executive Officer of Pfizer. “Patients who have arthritis pain may be able to benefit from our current formulation, which combines two COX-2-selective medications, and our COX-2 selectivity allows us to address the same underlying clinical challenges that we face with COX-2 inhibitors.”
Pfizer’s COX-2 selectivity allows it to treat patients with less-expensive, non-selective medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), which are used to lower pain and inflammation. Celebrex works by blocking an enzyme called COX-2, which breaks down molecules such as prostaglandins. These molecules are important to treating inflammation and pain and should be taken as directed. In some cases, Celebrex may not be appropriate for certain patients.
The development of Vioxx (rofecoxib) marks a significant step in Pfizer’s effort to bring a new drug to market that addresses the underlying biochemical problems that are commonly associated with COX-2 inhibitors, such as gastrointestinal bleeding and heart attack.
“Our COX-2 selectivity allows us to address the challenge that patients often face with COX-2 inhibitors,” said Ian Read, Pfizer Chief Executive Officer. “This new drug represents an important step forward in our ongoing efforts to bring innovative and safe pain management treatments to patients.”
Pfizer has already received FDA approval for the development of Vioxx (rofecoxib), a new generic version of Pfizer’s Celebrex arthritis pain reliever. The U. S. sales of Vioxx (rofecoxib) have been declining since the late 1990s, when it first received FDA approval for its use in treating arthritis pain. Vioxx is not indicated for the treatment of osteoarthritis or rheumatoid arthritis. Pfizer’s Celebrex (celecoxib) is indicated for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
Pfizer continues to be the world’s largest pharmaceutical company by revenue. It is the only major U. healthcare company to have annual sales of $1.7 billion for the last 12 months ending in October 2014. The company is the fourth-largest U. healthcare company by revenue, with $4.9 billion in sales in 2014.
Pfizer continues to work with healthcare providers and patients to develop new therapies that improve patients’ pain and reduce inflammation, and that may work for those who have a chronic condition. The company is also working with healthcare providers and patients to develop therapies that may be safer for patients with a history of heart disease.
Pfizer’s Celebrex (celecoxib) sales have increased in the fourth quarter of 2014, and are expected to continue growing at a compounded annual growth rate (CAGR) of 4% to 5% over the coming year. In the U. S., sales of the drug are expected to grow at a CAGR of 9% to 10% over the coming year. The company is seeking approval for the development of an oral formulation of Celebrex (celecoxib) for arthritis patients.For additional information about Celebrex and its COX-2 selectivity and other COX-2 inhibitors, please visit the Pfizer website at.
About Pfizeris a global leader in prescription medicines, with a strong presence in the U. and Canada. Its global headquarters are in the United States of America.
The cost of celecoxib for patients with rheumatoid arthritis is currently around $30 for a 30-mg tablet. However, prices may rise as a result of more frequent use of the drug.
Cancer, the second most common cancer in the United States, is on the rise with a projected population of approximately 6.8 million. Celebrex, marketed under the brand name CeleX, is one of a new class of drugs that is being developed by Pfizer. This new class of drug can be used to treat cancer and the potential side effects of its use are being considered. Celecoxib is being developed as a treatment for arthritis. However, it is being sold under the brand name CeleX for patients with rheumatoid arthritis. The US Food and Drug Administration (FDA) is evaluating the safety and efficacy of Celebrex to determine what is being marketed. Celebrex is being approved to treat moderate-to-severe rheumatoid arthritis in adults. Celecoxib, marketed under the name CeleX, is an anti-inflammatory drug that is currently under investigation in the US for the treatment of rheumatoid arthritis. Celebrex is used as an adjuvant therapy in postmenopausal women with advanced-stage breast cancer to reduce the risk of death from cardiovascular disease. Celebrex has been studied for the treatment of breast cancer and has also been used to treat rheumatoid arthritis in postmenopausal women, however, the results of clinical trials in this area have not been published. Celebrex has not been approved by the FDA for the treatment of rheumatoid arthritis in adults, and there have been concerns that its use is being studied in other countries outside of the US..
View/ShutterstockCelecoxib is the brand name of a drug that is being developed by Pfizer, a pharmaceutical company that makes a variety of products. Pfizer is the parent company of a group of pharmaceutical companies that make the brand name drug. The company is the company that developed Celebrex in the 1990s and has commercial rights in the brand name drug. Celebrex was approved to treat the treatment of rheumatoid arthritis in adults, and a randomized study of Celebrex in people with rheumatoid arthritis showed that people taking Celebrex had a lower risk of developing rheumatoid arthritis. However, it was not studied in people without rheumatoid arthritis. The new drug developed by Pfizer is being used as a treatment for arthritis in patients with rheumatoid arthritis and it is being studied as a potential adjuvant therapy to reduce the risk of cancer recurrence in those with rheumatoid arthritis. Celecoxib, marketed as, is being studied for the treatment of rheumatoid arthritis, a chronic inflammatory disease that causes joint damage and is being investigated for its potential to treat osteoarthritis. Celecoxib is being approved for the treatment of rheumatoid arthritis in adults in the United States.
Celecoxib, marketed as, is being studied for the treatment of rheumatoid arthritis in adults in the United States. The FDA has received concerns that Celecoxib may be given for the treatment of arthritis in patients with rheumatoid arthritis. The study of Celebrex in people with rheumatoid arthritis showed that people taking Celebrex had a lower risk of developing rheumatoid arthritis. Celecoxib, marketed as, is being studied for the treatment of rheumatoid arthritis in adults, and there have been concerns that its use is being studied in other countries outside of the US. Celebrex is being approved for the treatment of rheumatoid arthritis in adults in the United States.
NEW YORK -- The prices of popular drugs such as aspirin and Celebrex are increasing dramatically as prices for many drugs rise, the U. S. Food and Drug Administration announced Wednesday.
The Food and Drug Administration, the first to approve prescription drugs, said the drugs are among the most widely used and expensive drugs in the U. -- with more than $4.5 billion in prescriptions filled in 2008.
That's a significant increase compared to $2.4 billion in 2005, the agency said.
The drugs, which were developed by Merck & Co. in a joint effort with Johnson & Johnson, are being sold by some retail pharmacies in the U. While the FDA and the drug industry have long sought to limit prices of the drugs, the drugs are more widely available.
At least one pharmacy is now selling Celebrex and another is offering prices for the pills at Walgreens.
Walmart is one of the nation's largest and most profitable pharmaceutical companies, with more than 30 percent of the market.
But the prices for drugs like Celebrex and CeleX are going up, with more than $4 billion in prescriptions filled in 2008, the FDA said.
In addition to its $4.5 billion price increase, Walgreens has more than 20 percent of the company's sales.
The company said its price of the drug is about $3 per pill, up about 2.3 percent from when the company began promoting the drugs in 2002. It also said the company has a "lifestyle" drug program, called "POP," that is designed to help people take fewer doses of drugs than other companies do.
The company also said it is working on an alternative to the Food and Drug Administration's new label for the drug.
"We are working on a drug that works, and we are not just going to give the brand name," said Dan Solis, Walgreens spokesman.
The drug company said the FDA is continuing to work with the FDA's Office of Inspector General to evaluate and approve its use of the drugs.
The agency will report its final results of the agency's review of the drug and other drugs used in the treatment of arthritis or other inflammatory conditions. The drugs may help prevent heart attacks, strokes, or other gastrointestinal problems.
The drug is sold under a number of brand names, including Celebrex, Celecoxib, and Vioxx.
For patients, the drug also contains celecoxib, which is a nonsteroidal anti-inflammatory drug. But it is not available to all patients.
The company is also selling a generic version of Celebrex, called Vioxx, that is similar to Celebrex, but is less potent and may have less potential for side effects.
The FDA has said Vioxx is only available to patients with certain conditions, including those that affect the digestive system. The FDA does not approve a generic drug for the treatment of arthritis, but will only approve one, if necessary.
The company said that the FDA does not recommend the use of the Celebrex label for more than three years because it may lead to increased side effects.
The drug is also approved to treat high blood pressure.
The drug is available in the U. S., Canada, and Mexico. The FDA said it is working with the Food and Drug Administration to approve a generic version of Vioxx to treat high blood pressure.
The generic is Vioxx, sold under the brand name Celebrex. It is not available to patients or insurers.
The FDA said the companies that make Celebrex and Vioxx are also approved to use a similar drug that has similar mechanisms of action, such as inflammation and pain relief.
The FDA said the companies also are doing the research and developing the drugs to reduce the risk of heart attacks and strokes. The FDA said the companies are working with the FDA to approve the use of Vioxx for patients with high blood pressure.
Vioxx was approved for the treatment of high blood pressure, and patients who have heart problems also are prescribed Vioxx. The Food and Drug Administration will approve the drug in July for patients with heart problems.
In the meantime, the FDA is looking at other options for patients who are taking the drugs. The agency is also working with the FDA to approve a generic version of the drug called Vioxx, which has similar mechanisms of action.
There is also an alternative to the drug called Bextra, which works by blocking the production of cyclooxygenase enzymes.
Salt Composition in both
Salt Composition
Celecoxib 100mg(same for both)
You Searched
Strip of 10 capsules
We only sell the best substitute from top brands
Our Recommendation
Cobix 100mg Capsule 10s
832+ Customers trust this
WHO GMP Certified
Marketed by
Doctor ApprovedMedicine Comparison
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
Pantosec DSR 30/40mg PR Capsule 10sPantosec 40mg Tablet 10sCipvildin M 500/50mg Tablet 15sAb Rozu 10mg Tablet 10sCipcal D3 60000IU Capsule 4sCipcal 500mg/250IU Tablet 15sDapaquest 10mg Tablet 10sMontecip LC 5/10mg Tablet 10sLipvas 10mg Tablet 10sParacip 650mg Tablet 10sView More
Aerolife inhalation Device 1sAir Space Wit Exhle Valve Device 1sBp Monitor (Omron) Hem 8712 Device 1sContour Plus System 1sDigital Thermometer Mercury Device 1sDuohaler DPI Device 1sIbreathe DPI Inhealer Device 1sMachaler DPI Device 1sMacspacer Device 1sNovopen 4 | Diabetes Monitoring Devices 1s
For adults:
Pantosec 400mg Tablet 10s
Celebrex 400mg Tablet 15s
A healthcare provider will ask you about your health history before prescribing this medication. To help ensure you are covered by your insurance, your provider may ask you how you will pay for the treatment if prescribed. If you have any specific healthcare needs, your healthcare provider will make sure you are covered by your insurance. This healthcare provider examination is for adult healthcare professionals and is not considered medical or diagnostic.
This tablet is a'Peshawar approved' medication. It is used to treat: allergic rhinitis, chronic obstructive pulmonary disease (COPD), and asthma. It is also used to prevent heart attacks, strokes, and blood clots in adults and children 1 year or older. It works by relaxing muscles and increasing blood flow to the lungs. It comes in the form of 200mg tablets in capsule form.
Stade de France Pharmacy